Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized cellular immunotherapy against B cell malignancies. However, the complex and lengthy manufacturing processes involved in generating CAR T cell products ex vivo result in substantial production time...

Descripción completa

Detalles Bibliográficos
Autores principales: Huckaby, Justin T, Landoni, Elisa, Jacobs, Timothy M, Savoldo, Barbara, Dotti, Gianpietro, Lai, Samuel K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438880/
https://www.ncbi.nlm.nih.gov/pubmed/34518288
http://dx.doi.org/10.1136/jitc-2021-002737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438880/
https://www.ncbi.nlm.nih.gov/pubmed/34518288
http://dx.doi.org/10.1136/jitc-2021-002737

Ejemplares similares